Introduction and Medicinal uses of Amlodipine
Calcium channel blockers were introduced in 1988 for the management coronary heart diseases and later adopted towards management of hypertension. Initial management usage entailed treatment of angina, vascular diseases, and arrhythmic conditions. Amlodipine drug has been used as mediation for high blood pressures and diseases of the coronary artery. At times it can be used for management of high blood pressure related angina. It is ingested through the mouth and its effects last for days. Common side effects attributed to this medication entail tiredness, abdominal pain, swelling, and nausea. Its usage during pregnancy has not been established. Amlodipine acts by increasing the size of the arteries due to its long-acting nature of the calcium channel blocker. It exerts pressure on the third level generation of dihydropyridine (DHP) Calcium channel blockers and exerting an action through inhibition of calcium into the vascular system influx in smooth muscle cells and the myocardial cells leading to resistance to the vascular peripheries.
Amlodipine is on the list of World Health Organization List of medications and is categorized under safe medicines for administration. Its medicinal usage is listed for the management of hypertension and diseases of the coronary among people who are experiencing either stable or the vasopressin chest pains without indication of heart failure (Wang and Guang, 593). Further, it has been demonstrated to be effective through combined therapy for hypertension management or coronary heart complications. Administration of Amlodipine can be done to adults and children aged 6-17 years. Calcium channel blockers have been indicated to provide greater resistance and protection against the occurrence of strokes compared to other classes of blood pressure management drugs. Its combination with other calcium chain blockers is considered first-line management for Raynaud’s phenomenon (Baumhakel & Bohn, 207).
When used as a combined therapy, Amlodipine can form a combination of a wide variety of drugs. A combination of Amlodipine and atorvastatin is essential for the former being used for hypertensions while the latter used for the prevention of cardiovascular-related events in cases of high cholesterol. Amlodipine and combination of hydrochlorothiazide are used when the former cannot be able to manage and lower blood pressure. The combined therapy of benazepril and Amlodipine issued to block the angiotensin receptor antagonisms and block the renin-angiotensin system process. A combination of Amlodipine and perindopril is used if Amlodipine alone can lead to edema. Perindopril is used as a long-lasting ACE inhibitor in the body. A combined intake of valsartan and Amlodipine is used when the valsartan is used as an angiotensin II antagonist receptor.
Mechanism of Action
Amlodipine acts as an angio selective blocker of the calcium channel which inhibits calcium ions movements into the smooth vascular system and cardiac muscle cells through contraction of cardiac muscles and smooth cells of the vascular. The calcium ions are inhibited by Amlodipine moving across the cell membrane increasing an effect on the smooth vascular smooth cells. This action leads to the vasodilatation process and lowering of the effect of the vascular resistance reducing the overall blood pressure. The effect on the cardiac muscle leads to the prevention of constriction in the arteries of the coronary.
The negative effects occasioned on the entropy can be observed in vitro however it has not been demonstrated through therapy doses of animals. The two stereoisomers [R(+), S(–)], the (–) have been linked to being active compared to the + isomer (Karmoker, Joydhar, Sarkar & Rahman n.p). The concentrations of serum are not affected by the Amlodipine tracts on the currents of the channels of L type Cav1.3 located on the adrenal glands of the Zona glomerulosa (Ritter n.p).
The underlying mechanism of action entails stable angina and variant angina. Stable angina produces a reduction effect on the amlodipine through the resistance of the periphery against the actions of the heart and reduces the overall pressure, this mechanism leading to lowered levels of oxygen demand (Li & Robert, 2015). In the variant angina process, the amlodipine acts by blocking the spasms in the coronary artery and producing a flow of blood in the coronary arteries and arterioles through a response of the potassium, serotonin, epinephrine, and calcium (Learning, n.p). In the heart, the amlodipine acts on reducing the action of blood flow, this leads to increase delivery of oxygen to the myocardial tissues reducing its consumption. This leads to amlodipine beneficial effects on the management of angina due to multiple actions. Thus the calcium chain blockers exert favorable effects on the heart.
Dosage of amlodipine is undertaken once daily due to its long half-life, this has been observed to be favorable for compliance to patients. A startup dose of 5 mg is often recommended with a maximum dosage of 10 mg. Among the elderly population, 2.5 mg is often recommended. The onset of amlodipine is gradual on its action thus no need for activation of the neuroendocrine. The activation process of the mechanism reflex and increased heart rate has been observed to have adverse impacts on the metabolism of lipids and carbohydrates.
Adverse effects of amlodipine
Fundamental adverse effects of amlodipine entail effects on vasodilator, dizziness, edema peripheral, flushing, and palpitations. Peripheral edema occurs as a form of accumulation of fluid in the tissues and occurs at a dose of 10 mg with 10% being lost. This effect leads to the dilation of the arteries and the peripheral vessels. The elevated dilation process leads to increased blood flow leading to the inability to push in the constricted venues of the postcapillary and the vessels. The pressure generated leads to plasma being moved to the interstitial spaces the amlodipine association of the edema can be managed by administration and activation of the ACE inhibitors and the angiotensin antagonism receptors.
Fatigue occurrence has been observed to be related to dosing effects, nausea, the pain of the abdominal and somnolence. These side effects occur by 1 % through disorders of the blood, impotence, peripheral neuropathy, hepatitis, and jaundice occurrence. Amlodipine is linked to the growth of the gingival which is a common relative effect linked to its exposure. Further health of dental structure and plaque buildup are major risk factors (Gaur & Agnihotri, 610).
Amlodipine can react by increasing the risks of angina especially among persons with obstructive coronary heart disease after an increased increase of the dose intake. Amlodipine inhibits the constriction and restores the blood flow in the coronary arteries leading to a process that works independently on vascular smooth muscle leading to a reduction of the vascular resistance and reduction in the blood pressure levels. An overdose level has been observed with the intake of amlodipine leading to toxicity, low blood pressure, and increased heart rate. Toxicity management is undertaken with fluid replacement, ECG monitoring process, and vitals respiratory system assessment, kidney function, electrolyte levels and output of urine. The administration of vasopressors can lower the blood pressure when the resuscitation of fluid is not sufficient (Pillay, n.p).
Among these adverse effects, peripheral edema has been viewed as an aspect of hindering compliance. The underlying adverse effects are managed by administering an agent before bedtime and lowering the dosage intake per day. Studies have shown that bedtime intake of nifedipine gastrointestinal is linked to a 93% lowering levels of edema compared to doses administered by the morning. Other studies have shown that the adverse effects linked to nausea, dizziness, fatigue, and palpitations are not justified enough to cause drug discontinuation. Among breastfeeding mothers, Amlodipine traces are contraindicated in breastfeeds, unstable angina and cardiogenic shock. Further, the emergence effects of vasodilatation have been shown to lead to lowered levels of cardiac output in aortic stenosis process (Agnuhotreti et al. , n.p).
Risk factors
Risks factors have demonstrated that pregnancy and lactation play crucial aspects regarding the medication processes. Pregnancy has shown a lack of sufficient data to assess risks associated with the occurrence of birth defects and miscarriages linked to pregnancy dosages. Increased levels of blood pressures elevate the risks of pregnancy and increase pre-eclampsia risks, gestational diabetes, complications n during delivery and premature births. Associated fetal risks are the growth of inter uterine restrictions and the death of inter uterine. Data obtained from animal studies have indicated no adverse effects on the administration of amlodipine. Presence in breast milk has been observed, though no adverse risks found.
Interactions
Interactions of amlodipine have been shown to occur on several drug interaction processes leading to increased levels in the body. The CYP3A inhibitors are an exemplar class of drugs, other drug classes entail the diltiazem calcium channel blockers, clarithromycin and anti fungal. The effects of Amlodipine lead to increased levels of tacrolimus, simvastatin, and cyclosporine (Zuo et al., 398-405). An increased dosage of greater than 20 mg simvastatin which acts as a lipid-lowering agent is administered with amlodipine, myopathy risks increase while administering Viagra with amlodipine increases hypotension risks.
Co-administration of amlodipine and acebutolol has shown to reduce the action of angina and improved tolerance to exercise. Combine administration of these drugs hypotension and cardiac performance impairment can occur. This has been observed especially with patients diagnosed with ventricular dysfunction. Interactions with butalbital, codeine, caffeine, and acetaminophen have shown an increased in codeine related reactions which entail respiratory and sedation. The codeine has been shown to the metabolized by the CYP2D6 to morphine and norcodeine by the CYP3A4. The norcodeine has been shown not to have any analgesic properties, as is a weaker inhibitor. Increased and concomitant usage has been observed to lead to increased rates of codeine plasma concentrations leading to increased metabolism of CYP2D6 and elevated levels of concentrations of morphine.
Interaction with Alfentanil has been shown to affect the reduction of dosage and monitoring of respiratory depression and sedation when amlodipine is used. Discontinuation of amlodipine leads to an increase in the dosage of alfentanil until stable drug effects are maintained. Action on the alprostadil combination with calcium channel blockers has been observed to induce additive hypotension, thus caution has been advised in this combination process. Intake of amifostine drugs combined with calcium channel blockers needs to managed and monitored closely during infusions due to its effects of additively. Patients being and administered amifostine undergoing chemotherapy needs to be discontinued preceding its administration (Kim et al., 2475).
Amoxicillin co-administration with amlodipine has been shown to affect geriatric patients due to increased risks of acute kidney injury and the occurrence of hypotension. Amlodipine is a strong substrate of CYP3A4 and amoxicillin is a strong inhibitor of CYP3A4. Another common drug interaction is the use of aspirin. A reduced dosage of oxycodone is preferred for respiratory management is concurrent use of amlodipine is necessary.
Interaction has been observed with Tipranavir. Amlodipine is a CYP3A4 substrate; typically such antiretroviral inhibitors of protease have shown an increase in the concentration of amlodipine through its inhibition leading to effects on the hypotension levels of patients. There is a need for exercising n cautions while using antiretroviral inhibitors of protease during co-administration with amlodipine and the resulting therapeutics response monitored. Intake of nonsteroidal anti-inflammatory drugs and antihypertensive drugs are co-administered, monitoring of patients’ vital signs and symptoms needs to be focused to determine insufficient of the renal and blood pressure levels. Drug medication prescription of anti-hypertension often require adjustments among patients receiving concurrent NSAIDs, as they have been linked to increased blood pressure. The occurring effect often is a long-lasting one, NSAIDs can lead to dose-dependent reductions in the formation of prostaglandin which often leads to reduced flow of blood leading to insufficiency of renal and elevated blood pressure which is often accompanied by peripheral edema and increased weight (Hsiao et al., 407-417).
Diclofenac belongs to the NSAID class of drugs and antihypertensive drugs are used concurrently. During this stage, carefully patients’ monitoring process is ensured to assess signs of the inefficiency of renal and control of blood pressure. The significant effect has been observed among patients receiving long term NSAID therapy medication. It causes dose dependency on prostaglandin reduction which may lead to a reduction in blood flow leading insufficiency of the renal and increased blood pressure and peripheral edema and increased gain in weight. Patients using renal prostaglandins may have a reduction of the renal blood flow with the use of NSAIDs.
Concomitant usage of dihydrocodeine with amlodipine has been shown to increase the concentration of plasma leading to increase CYP2D6 metabolisms, increasing the concentration in the concentration of the plasma. If co-administration is relevant, patient intervals are monitored and dosage requirements reviewed. Discontinued the administered of amlodipine could lead to decrease ion dihydrocodeine plasma concentrations, reducing the efficacy of the opioid and leading to withdrawal effects due to dependency on dihydrocodeine.
Carbinoxamine co-administration with amlodipine has shown an increase in adverse reactions entailing depression of respiration and sedation. If the co-administration is necessary there is a need for reducing the dose of dihydrocodeine, while if amlodipine is necessary then there is a need for monitoring for possible withdrawal effects on the patients due to related physical dependence on the drugs.
Interaction of verapamil which is non -dihydropyridine calcium channel blocker and amlodipine have been observed, leading to the possible occurrence of impaired cardiac performance and hypotension occurrence among patients diagnosed with left ventricular dysfunction. The interaction occurring between the inhibition nature and substrate aspect can lead t an increase in amlodipine systemic exposure among elderly hypertensive patients. Tramadol effects have shown a need for reduced reduction with co-administration with amlodipine until a stable drug state is achieved. Close monitoring of patients with serotonin syndrome and sedation signs and depression of depression is observed. Depression of the respiratory can be fatal with an increased state of amlodipine administration. Its concurrent use being a weak CY3A4 inhibitor leads to increase the exposure of tramadol leading to increased CYP2D6 metabolisms thus increasing the metabolite exposure of M1 which is potent mu-opioid agonists (Ahamad, Rana & Rooba, 555-567).
Pharmacokinetics
Amlodipine is taken through oral intake with an approximate 93% plasma bound proteins. Amlodipine is metabolized extensively by inactive compounds found in the liver with an estimate of 10% parent compound, and 60% of the inactive metabolites removed in the urine. The half-life is estimated to be between 30 to 50 hours. A steady supply of amlodipine is after approximately 7 to 8 days of daily dosage. The drug is affected by the cytochrome p450 iso-enzymes and the transporters of the drugs CYP3A4. The substrate nature is affected by the inhibiting properties of CYP3A4 or its inducers. Oral administration has been demonstrated to be effective and allows peak plasma levels. It is reached between 6-12 hours. The bioavailability of oral intake is between 64% and 90% and is not affected by food (Park et al., n.p).
Amlodipine is a long-acting calcium channel antagonist that acts through selective action on inhibition of calcium ion influx in the cell membranes (Ananchenko et al., 35). The target is on the L type channels of calcium located in the muscle cells and the calcium N-type channels in the central nervous system. They are involved in the signaling of the nociceptive signaling and perception of pain. The amlodipine plays inhibitory effects on the influx of calcium in the smooth muscles and lowers the contraction process. The resultant effect of the amlodipine is a reduction of the total resistance of the vascular without any change so the decree of cardiac output occasioned on the pressure product rates and the contractibility compared to the verapamil which is a nondihydropyridine. A treatment lasting for one month on amlodipine, the output of cardiac is enhanced significantly compared to the verapamil which can affect emotional arousal and reduce the load on the cardiac without elevating the demands of the cardiac output. In this case, amlodipine increases the response with an increase in the cardiac load increase levels.
Works cited
Agnihotri, Rupali, Giliyar Bhat, and Khandige Bhat. “Amlodipine-induced gingival overgrowth: considerations in a geriatric patient.” Geriatrics and Gerontology International 11.3 (2011): 365-368.
Ahmad, Rana M., and Orooba MS Ibrahim. “Effect of erythromycin on pharmacokinetics of Amlodipine in hypertensive rabbits.” Online Journal of Veterinary Research 23.6 (2019): 555-567.
Ananchenko, Gennady, Jasmina Novakovic, and Johnathan Lewis. “Amlodipine besylate.” Profiles of Drug Substances, Excipients and Related Methodology. Vol. 37. Academic Press, 2012. 31-77.
Baumhäkel, Magnus, and Michael Böhm. “Recent achievements in the management of Raynaud’s phenomenon.” Vascular health and risk management 6 (2010): 207.
Gaur, Sumit, and Rupali Agnihotri. “Is dental plaque the only etiological factor in Amlodipine induced gingival overgrowth? A systematic review of evidence.” Journal of clinical and experimental dentistry 10.6 (2018): e610.
Hsiao, Hsiu‐ling, et al. “Pharmacokinetic drug–drug interaction assessment between LCZ696, an angiotensin receptor neprilysin inhibitor, and hydrochlorothiazide, amlodipine, or carvedilol.” Clinical pharmacology in drug development 4.6 (2015): 407-417.
Karmoker, James Regun, et al. “Comparative in vitro evaluation of various commercial brands of amlodipine besylate tablets marketed in Bangladesh.” Asian Journal of Pharmaceutical and Health Sciences 6.1 (2016).
Kim, Jung-ryul, et al. “No pharmacokinetic interactions between candesartan and amlodipine following multiple oral administrations in healthy subjects.” Drug design, development and therapy 12 (2018): 2475.
Park, Jin‐Woo, et al. “Pharmacokinetic and haemodynamic interactions between amlodipine and losartan in human beings.” Basic & clinical pharmacology & toxicology (2019).
Pillay, V. V. Modern medical toxicology. Vol. 4. Jaypee Brothers Medical Publishers (P) Ltd, 2013.
Ritter, James, et al. A textbook of clinical pharmacology and therapeutics. CRC Press, 2008.
Spratto, George, and Adrienne Woods. Delmar Nurse’s Drug Handbook 2012 Edition. Nelson Education, 2011.
Wang, Ji-Guang. “A combined role of calcium channel blockers and angiotensin receptor blockers in stroke prevention.” Vascular health and risk management 5 (2009): 593.
Zuo, Xiao-cong, et al. “Effect of CYP3A5* 3 polymorphism on pharmacokinetic drug interaction between tacrolimus and amlodipine.” Drug metabolism and pharmacokinetics 28.5 (2013): 398-405.
